Skip to main content
. Author manuscript; available in PMC: 2021 Jun 10.
Published in final edited form as: J Invest Dermatol. 2016 Dec 21;137(5):1033–1041. doi: 10.1016/j.jid.2016.12.007

Figure 4. Several complementary methods suggest that fresolimumab nonimprovers may have benefitted from MMF treatment.

Figure 4.

(a) Density plot of the rank-biased overlap (RBO) null distribution (permuted SVM scores). The red arrow indicates the true RBO (0.34) between fresolimumab base and MMF post ranked lists. (b) Boxplot illustrating that fresolimumab base bottom-ranked gene sets of increasing size (100, 250, 500, and 1,000 genes) have significantly highly positive MMF post-SVM scores. (c) Schematic overview of findings. Fresolimumab nonimprovers have elevated immune-related genes pretreatment; immune-related genes are uniquely decreased in MMF improvers. MMF, mycophenolate mofetil; SVM, support vector machine; TGF-β, transforming growth factor-β.